Table 1.

Description of characteristics of the included studies.

First Author	year of publication	study year	country	population	Age	F/M	Interval between transplantation and vaccination (years)	Years on dialysis	NOS
Beyer	1987	1985–1986	Netherlands	HD	57(17,76)	55/53	NA	2(0.2,12)	S2;C2;O3;T7
Vogtlander	2004	1998–1999	Netherlands	HD	70	22/22	NA	2.7	S4;C2;O2;T8
Tanzi	2007	2003–2004	Italy	HD	65.3 ± 13.5	23/35	NA	NA	S0;C2;O3;T5
Song	2006	2003–2004	Korea	HD	50.0 ± 6.9	17/23	NA	2.2 ± 1.1	S4;C1;O2;T7
				HD_C	48.6 ± 6.7	25/20	NA	1.8 ± 0.8
Scharpe	2009	2003–2004	Belgium	HD	67 ± 14	79/122	NA	3.83 ± 4.67	S2;C2;O1;T5
Scharpe	2008	2003–2004	Belgium	RT	56 ± 13	60/105	6.3(3.1,10.4)	NA	S3;C2;O3;T8
Quintana	2013	2009–2010	Spain	HD	59.84 ± 15	24/34	NA	3.83 ± 4.70	S2;C2;O3;T7
				PD	55.29 ± 14.72	5/9	NA	2.08 ± 1.1
				RT	54.04 ± 12.04	26 % 26	6.88 ± 7.28	NA
Brakemeier	2012	2009–2010	Germany	RT	52.2 ± 15	NA	>=0.5	NA	S1;C2;O3;T6
Le Corre	2012	2009–2010	France	RT	50.9(20,64)	32/89	3.4 (0.5,31)	NA	S2;C2;O3;T7

Note. HD, hemodialysis; HD_C, control group who was hemodialysis patient receiving one dose of vaccine;

PD, peritoneal dialysis; RT, renal transplant; F/M, female/male; NA, not available;

NOS, the Newcastle–Ottawa Scale for cohort studies; S_N, the number of stars for cohort selection section;

C_N, the number of stars for cohort comparability section; O_N, the number of stars for cohort outcome section;

T_N, the total number of stars.